Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post- Transplantation Cyclophosphamide-Based Haploidentical Transplantation with.

Slides:



Advertisements
Similar presentations
Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.
Advertisements

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome  Philippe Armand,
Comparison of Allogeneic Stem Cell Transplantation from Familial- Mismatched/Haploidentical Donors and from Unrelated Donors in Adults with High-Risk.
Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Sabina Kersting, Leo F. Verdonck 
A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide 
Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.
Posttransplant Autoimmune Hemolytic Anemia and Other Autoimmune Cytopenias are Increased in Very Young Infants Undergoing Unrelated Donor Umbilical Cord.
Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.
Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-,
Betty T. Tran, Abigail Halperin, Jason W. Chien 
Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation  Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan.
Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.
Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions  Darius Sairafi, Mats Remberger, Michael.
T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar.
Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma  Robert Chen, Joycelynne.
Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.
Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia 
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma  Peter Dreger, Ginna.
Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:
Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program  Margaret L.
Biology of Blood and Marrow Transplantation
Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among.
Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage.
Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation  Lindsay G. Jensen, Tracey Stiller,
A Well-Tolerated Regimen of 800 cGy TBI-Fludarabine-Busulfan-ATG for Reliable Engraftment after Unmanipulated Haploidentical Peripheral Blood Stem Cell.
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation  Betul Oran, John E. Wagner, Todd.
Paul A. Hoffmeister, Sangeeta R. Hingorani, Barry E. Storer, K
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan.
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Statistical Considerations in Studies of Late Effects in HCT
Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.
Granulocyte Colony-Stimulating Factor–Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host.
Comparison of Autologous Stem Cell Transplantation versus Haploidentical Donor Stem Cell Transplantation for Favorable- and Intermediate-Risk Acute Myeloid.
Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning 
Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High- Risk Acute Lymphoblastic Leukemia  Samer A. Srour, Denái R. Milton,
Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic.
Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation  Merav Bar, Weigang Tong, Megan Othus,
Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic.
High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
T Cell–Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an.
CD56 Enriched Donor Cell Infusion Following Post-Transplantation Cyclophosphamide and Cyclosporine Alone for Haploidentical PBSCT in Myeloid Malignancies.
Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.
Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation  Stefan O. Ciurea, Victor Mulanovich,
Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for Treatment of Hematologic Malignancies in Children  Xiaojun.
Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients.
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and.
Blood and Marrow Transplant Handbook
Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease  Haydar Frangoul, Li.
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Mary Eapen  Biology of Blood and Marrow Transplantation 
In Memoriam: E. Donnall Thomas
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease 
Presentation transcript:

Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post- Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor–Mobilized Donor Lymphocyte Infusions  Sarita Rani Jaiswal, Shamsuz Zaman, Aditi Chakrabarti, Subrata Sen, Shashwata Mukherjee, Sneh Bhargava, Kunal Ray, Paul V. O'Donnell, Suparno Chakrabarti  Biology of Blood and Marrow Transplantation  Volume 22, Issue 10, Pages 1867-1873 (October 2016) DOI: 10.1016/j.bbmt.2016.07.016 Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidences of (A) aGVHD, (B) cGVHD, (C) NRM, and (D) disease progression. The solid line represents the MAC-DLI group, and the broken line represents the MAC group. Biology of Blood and Marrow Transplantation 2016 22, 1867-1873DOI: (10.1016/j.bbmt.2016.07.016) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 (A) OS and (B) PFS: solid line represents MAC-DLI group, and the broken line represents the MAC group. Biology of Blood and Marrow Transplantation 2016 22, 1867-1873DOI: (10.1016/j.bbmt.2016.07.016) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.